Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019



Summary



GlobalData, the industry analysis specialist, has released its new report, “Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Toxoplasmosis Therapeutics market. The report identifies the key trends shaping and driving the global Toxoplasmosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Toxoplasmosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.



Scope


The report provides information on the key drivers and challenges of the Toxoplasmosis Therapeutics market. Its Scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Toxoplasmosis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Toxoplasmosis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Toxoplasmosis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Toxoplasmosis Therapeutics market



Reasons to buy


The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Toxoplasmosis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Toxoplasmosis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Toxoplasmosis Therapeutics market landscape? – Identify, understand and capitalize.

Table Of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Toxoplasmosis Therapeutics - Introduction 6
2.1 Disease Overview 6
2.1.1 Types of Toxoplasma gondii Strain 7
2.1.2 Life Cycle and Transmission 7
2.2 Epidemiology 7
2.2.1 Historic Epidemiology (2006-2011) 8
2.2.2 Forecast Epidemiology (2011-2019) 9
2.3 Etiology 10
2.3.1 Food-borne Transmission 10
2.3.2 Congenital Transmission 10
2.3.3 Zoonotic Transmission 10
2.3.4 Rare Instances of Transmission 10
2.4 Pathophysiology 10
2.5 Signs and Symptoms 11
2.6 Commonly Used Diagnostic Tests 12
2.6.1 Types of Diagnostic Test 12
2.7 Treatment and Management Options for Toxoplasmosis 13
2.7.1 Management of Toxoplasmosis Infection during Gestation 14
2.7.2 Congenital Toxoplasmosis 14
2.7.3 Ocular Toxoplasmosis 15
2.7.4 Toxoplasmosis in Immunocompetent Patients 15
2.8 GlobalData Pipeline Report Guidance 16
3 Toxoplasmosis Therapeutics - Market Characterization 17
3.1 Toxoplasmosis Therapeutics Market Size (2006-2011) - Global 17
3.2 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Global 19
3.3 Toxoplasmosis Therapeutics Market Size (2006-2011) - The US 20
3.4 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - The US 21
3.5 Toxoplasmosis Therapeutics Market Size (2006-2011) - France 22
3.6 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - France 23
3.7 Toxoplasmosis Therapeutics Market Size (2006-2011) - Germany 24
3.8 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Germany 25
3.9 Toxoplasmosis Therapeutics Market Size (2006-2011) - Italy 26
3.10 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Italy 27
3.11 Toxoplasmosis Therapeutics Market Size (2006-2011) - Spain 28
3.12 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Spain 29
3.13 Toxoplasmosis Therapeutics Market Size (2006-2011) - The UK 30
3.14 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - The UK 31
3.15 Toxoplasmosis Therapeutics Market Size (2006-2011) - Japan 32
3.16 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Japan 33
3.17 Drivers and Barriers for the Toxoplasmosis Therapeutics Market 34
3.17.1 Drivers for the Toxoplasmosis Therapeutics Market 34
3.17.2 Barriers for the Toxoplasmosis Therapeutics Market 34
3.18 Opportunity and Unmet Need Analysis 35
3.19 Key Takeaway 36
4 Toxoplasmosis Therapeutics - Competitive Assessment 37
4.1 Overview 37
4.2 Strategic Competitor Assessment 37
4.3 Product Profiles of the Marketed Products in the Toxoplasmosis Therapeutics Market 38
4.3.1 Daraprim (pyrimethamine) 38
4.3.2 Spiramycin 39
4.3.3 Sulfadiazine 39
4.3.4 Folinic Acid 40
4.4 Key Takeaway 40
5 Toxoplasmosis Therapeutics - Pipeline Assessment 41
5.1 Overview 41
5.2 Strategic Pipeline Assessment 41
5.2.1 Toxoplasmosis Therapeutics - Phase III Clinical Pipeline 41
5.3 Key Takeaway 41
6 Toxoplasmosis Therapeutics - Clinical Trial Mapping 42
6.1 Clinical Trials by Region and Country 42
6.2 Clinical Trials by Phase 43
6.3 Clinical Trials by Trial Status 44
6.4 Clinical Trial Mapping by Sponsors 45
6.5 Prominent Sponsors 46
6.6 Companies Participating in Toxoplasmosis Therapeutics Clinical Trials 46
7 Toxoplasmosis Therapeutics - Strategic Assessment 47
7.1 Key Events Impacting the Future Market 47
7.2 Toxoplasmosis Therapeutics: Implications for Future Market Competition 47
8 Toxoplasmosis Therapeutics Market - Licensing and Partnership Deals 48
9 Toxoplasmosis Therapeutics Market - KOL Insights, 2012 49
10 Toxoplasmosis Therapeutics - Appendix 50
10.1 Market Definitions 50
10.2 Acronyms 50
10.3 Bibliography 50
10.4 Research Methodology 52
10.4.1 Coverage 52
10.4.2 Secondary Research 52
10.4.3 Forecasting 53
10.4.4 Primary Research 55
10.4.5 Expert Panel Validation 56
10.5 Contact Us 56
10.6 Disclaimer 56

List of Tables

Table 1: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2006-2011 8
Table 2: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2011-2019 9
Table 3: Alternative Antibiotics Used in Ocular Toxoplasmosis 15
Table 4: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011 18
Table 5: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 2011-2019 19
Table 6: Toxoplasmosis Therapeutics Market, The US, Revenue ($m), 2006-2011 20
Table 7: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2011-2019 21
Table 8: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 2006-2011 22
Table 9: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 2011-2019 23
Table 10: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 24
Table 11: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 2011-2019 25
Table 12: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 26
Table 13: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 2011-2019 27
Table 14: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 28
Table 15: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 2011-2019 29
Table 16: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 30
Table 17: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 2011-2019 31
Table 18: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 2006-2011 32
Table 19: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 2011-2019 33
Table 20: Toxoplasmosis Therapeutics-Phase III Pipeline, 2012 41
Table 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012 42
Table 22: Toxoplasmosis Therapeutics - Clinical Trials by Phase, 2012 43
Table 23: Toxoplasmosis Therapeutics - Clinical Trials by Status, 2012 44
Table 24: Toxoplasmosis Therapeutics - Overall Sponsors, 2012 45
Table 25: Toxoplasmosis Therapeutics - Prominent Sponsors, 2012 46
Table 26: Toxoplasmosis Therapeutics - Company Participating in Therapeutics Clinical Trials, 2012 46
Table 27: Toxoplasmosis-Global, Deals, 2012 48
Table 28: Toxoplasmosis Therapeutics Market, Global, KOL Insights, 2012 49

List of Figures

Figure 1: Diagnosis Algorithm for Congenital Toxoplasmosis 12
Figure 2: Approaches for the Treatment of Pregnant Women 14
Figure 3: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011 18
Figure 4: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 2011-2019 19
Figure 5: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2006-2011 20
Figure 6: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2011-2019 21
Figure 7: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 2006-2011 22
Figure 8: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 2011-2019 23
Figure 9: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 24
Figure 10: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 2011-2019 25
Figure 11: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 26
Figure 12: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 2011-2019 27
Figure 13: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 28
Figure 14: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 2011-2019 29
Figure 15: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 30
Figure 16: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 2011-2019 31
Figure 17: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 2006-2011 32
Figure 18: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 2011-2019 33
Figure 19: Opportunity and Unmet Need in the Toxoplasmosis Therapeutics Market 36
Figure 20: Toxoplasmosis Therapeutics - Strategic Competitor Assessment, 2012 38
Figure 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012 42
Figure 22: Toxoplasmosis Therapeutics - Clinical Trials by Phase, 2012 43
Figure 23: Toxoplasmosis Therapeutics - Clinical Trials by Status, 2012 44
Figure 24: Toxoplasmosis Therapeutics - Overall Sponsors, 2012 45
Figure 25: Toxoplasmosis Therapeutics Market, Drivers and Barriers, 2012 47
Figure 26: Implications for Future Market Competition in the Toxoplasmosis Therapeutics Market, 2012 47
Figure 27: GlobalData Market Size Estimation 53
Figure 28: GlobalData Market Forecasting Model 55

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 5 369
  • Industry report
  • May 2014
  • by Firstword Pharma

Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until recently it has been underserved in terms of effective therapeutic options. However, a revolution in personalised and ...

A Product and Pipeline Analysis of the Global Diabetes Therapeutics Market

A Product and Pipeline Analysis of the Global Diabetes Therapeutics Market

  • $ 5 000
  • Industry report
  • April 2014
  • by Frost & Sullivan

The marketed and development product landscape for diabetes therapeutics is becoming crowded with multiple products with little differentiation. However, there is still ample room for growth through the ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.